The Role of Diaphragmatic Surgery During Interval Debulking After Neoadjuvant Chemotherapy An Analysis of 74 Patients With Advanced Epithelial Ovarian Cancer

被引:9
作者
Tsolakidis, Dimitris [1 ]
Amant, Frederic [1 ]
Van Gorp, Toon [1 ]
Leunen, Karin [1 ]
Neven, Patrick [1 ]
Vergote, Ignace [1 ]
机构
[1] Katholieke Univ Leuven, Div Gynecol Oncol, Dept Obstet & Gynaecol, Univ Hosp Leuven, B-3000 Louvain, Belgium
关键词
Interval debulking; Diaphragmatic surgery; Coagulation; Stripping; Advanced ovarian cancer; ADVANCED OVARIAN-CANCER; CARCINOMA; MANAGEMENT; PROGNOSIS; RESECTION; SURVIVAL;
D O I
10.1111/IGC.0b013e3181d4de23
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: The purpose of this retrospective study was to evaluate diaphragmatic surgery in achieving optimal cytoreductive results and its associated complications during interval debulking surgery in patients with advanced ovarian cancer. Methods: After retrospective review of medical records, diaphragmatic surgery was performed in 74 of 128 consecutive patients with advanced epithelial ovarian cancer who underwent interval debulking, between September 1993 and December 2007. Four different approaches were performed: coagulation (group 1), stripping (group 2), combination of stripping with coagulation (group 3), and diaphragm full-thickness resection including muscle with pleura (group 4). Cytoreductive outcome, morbidity, overall survival, and disease-free survival were analyzed. Results: Two patients (2.7%) had International Federation of Gynecology and Obstetrics stage IIIB disease; 46 (62.16%), stage IIIC; and 26 (35.13%), stage IV. After 3 to 4 cycles of neoadjuvant platinum-based chemotherapy, the diaphragmatic disease was coagulated in 43 patients (58.10%) and was only stripped in 10 (13.51%); in 19 patients (25.67%), a combination of these techniques was applied; and in 2 (2.70%), the disease was resected, with the adjacent infiltrated part of the diaphragmatic muscle and the pleura above it. Debulking to no residual was achieved in 95%, 100%, 100%, and 50% for groups 1, 2, 3, and 4, respectively. The median disease-free survival was 15, 14, and 14 months, and the median overall survival was 34, 30, and 51 months for groups 1, 2, and 3, respectively, and were not reached for group 4. Minor and major complications were comparable among the groups. Pleural effusions were the most frequent associated complication, and chest tube placement (1.3%) or thoracocentesis (4%) were necessary for the relief of respiratory distress. The perioperative mortality rate was 0%. Conclusions: Diaphragmatic surgery during interval debulking enhances optimal cytoreduction rates and improves survival with acceptable and manageable morbidity. In patients with thick (94 mm) or large (91 cm) lesions, stripping the diaphragm or full-thickness resection of the diaphragmatic muscle is preferred.
引用
收藏
页码:542 / 551
页数:10
相关论文
共 22 条
  • [1] [Anonymous], COMMON TOXICITY CRIT
  • [2] [Anonymous], P 12 BIENN M INT GYN
  • [3] Ansquer Y, 2001, CANCER, V91, P2329, DOI 10.1002/1097-0142(20010615)91:12<2329::AID-CNCR1265>3.3.CO
  • [4] 2-L
  • [5] A GLOSSARY FOR REPORTING COMPLICATIONS OF TREATMENT IN GYNECOLOGICAL CANCERS
    CHASSAGNE, D
    SISMONDI, P
    HORIOT, JC
    SINISTRERO, G
    BEY, P
    ZOLA, P
    PERNOT, M
    GERBAULET, A
    KUNKLER, I
    MICHEL, G
    [J]. RADIOTHERAPY AND ONCOLOGY, 1993, 26 (03) : 195 - 202
  • [6] What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
    Chi, D. S.
    Eisenhauer, E. L.
    Lang, J.
    Huh, J.
    Haddad, L.
    Abu-Rustum, N. R.
    Sonoda, Y.
    Levine, D. A.
    Hensley, M.
    Barakat, R. R.
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 559 - 564
  • [7] Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer
    Eisenhauer, Eric L.
    D'Angelica, Michael I.
    Abu-Rustum, Nadeem R.
    Sonoda, Yukio
    Jarnagin, William R.
    Barakat, Richard R.
    Chi, Dennis S.
    [J]. GYNECOLOGIC ONCOLOGY, 2006, 103 (03) : 871 - 877
  • [8] What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer?
    Eisenkop, SM
    Spirtos, NM
    [J]. GYNECOLOGIC ONCOLOGY, 2001, 82 (03) : 489 - 497
  • [9] Role of surgery in ovarian carcinoma
    Fader, Amanda Nickles
    Rose, Peter G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (20) : 2873 - 2883
  • [10] Griffiths C T, 1975, Natl Cancer Inst Monogr, V42, P101